Publications

Add filters (0)

113 results

Viewing results for diabetes

Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.

August 17, 2026

Am J Physiol Cell Physiol

Abstract In type 2 diabetes (T2D), kidney fibrosis drives the progression of chronic kidney disease (CKD) and kidney failure. Lower urinary levels of collagen type III degradation (C3M), a biomarker of extracellular matrix (ECM) turnover, have been associated with CKD progression. We investigated the effect of combination therapy with renin-angiotensin system inhibition (RASi) and glucagon-like […]

Read publication

Proteomic analysis of plasma and extracellular vesicles from subjects with impaired vascular health.

August 7, 2026

Biosci Rep

Abstract Cardiovascular diseases are the leading cause of mortality worldwide, with atherosclerosis and formation of arterial plaques being a major underlying cause. Rupture or erosion of the plaque fibrous cap can result in thrombus formation, arterial occlusion, and a stroke or myocardial infarction. Plaque changes, and endothelial cell barrier leakiness, may result in material leakage, […]

Read publication

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers.

July 25, 2026

J Hepatol

Abstract Not all biomarkers are equal, and some should not be termed biomarkers. Despite an explosion in putative biomarker discoveries from high-throughput proteomic technologies, very few advance beyond initial excitement to become validated, clinically actionable tools. Most stall in a “biomarker valley of death,” where promising signals fail to meet robust technical, scientific, and regulatory […]

Read publication

Extracellular matrix proteins as risk markers for complications in type 1 diabetes.

June 20, 2026

Diabet Med

Abstract AIMS Kidney fibrosis, characterised by impaired extracellular matrix remodelling and excessive collagen deposition, is a hallmark of chronic kidney disease in diabetes. We investigated whether biomarkers reflecting collagen formation and degradation were associated with complications in type 1 diabetes. METHODS In this observational cohort study, markers of collagen type III (PRO-C3), VII (PRO-C7) and […]

Read publication

Accelerated basement membrane remodeling and serum matrix fragments as biomarkers of fibrosis in Alport syndrome.

May 26, 2026

Cell Rep

Abstract Chronic kidney disease (CKD) is characterized by fibrosis. Alport syndrome, a common monogenic form of CKD caused by collagen type IV variants, leads to basement membrane defects and progressive fibrosis. Understanding extracellular matrix dynamics is crucial for identifying disease-specific biomarkers and optimizing therapeutic timing. We applied a discovery approach combining stable C-lysine metabolic labeling […]

Read publication

Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy.

May 1, 2026

JACC Adv

Abstract BACKGROUND Novel collagen-derived circulating peptides, such as endotrophin, have been proposed as biomarkers of myocardial fibrosis. OBJECTIVES We aimed to determine the effect of pirfenidone, an antifibrotic agent, on circulating levels of these peptides, and their association with cardiovascular magnetic resonance extracellular volume (ECV). METHODS In the PIROUETTE (Pirfenidone in Patients with Heart Failure […]

Read publication

Characterization of a novel assay for full-length endotrophin in heart failure with preserved ejection fraction.

March 18, 2026

Sci Rep

Abstract Endotrophin is a matrikine released from the C-terminus of the alpha-3 chain of type VI collagen, gaining increasing attention both as a biomarker and as a therapeutic target in the cardiometabolic space. So far, it has been quantified in circulation by the PRO-C6 assay, which detects different-sized proteolytic fragments of the C-terminus, including endotrophin. […]

Read publication

Collagen type I degradation peptide as a predictive biomarker for mortality in ST-elevated myocardial infarction.

March 4, 2026

Clin Res Cardiol

Abstract BACKGROUND AND AIMS Tissue remodelling and extracellular matrix (ECM) changes are primary consequences of ST-elevated myocardial infarction (STEMI), leading to an increased risk of developing heart failure and mortality. Collagen type I is the top constituent of the cardiac ECM and is rapidly degraded at sites of tissue injury occurring in STEMI. We aimed […]

Read publication

Circulating endotrophin reflects inflammaging and mortality risk in older adults.

February 23, 2026

Geroscience

Abstract Although interest in biomarkers of biological aging is growing, consensus on reliable, non-invasive indicators remains limited. Endotrophin, a bioactive fragment released during collagen type VI formation, reflects fibroblast activation and extracellular matrix remodeling and has been linked to chronic diseases, metabolic dysfunction, and inflammation. Whether circulating endotrophin also captures aging-related phenotypes and mortality risk in […]

Read publication

Endotrophin as a biomarker and mediator in cardiovascular-kidney-metabolic syndrome: current insights and remaining questions.

February 1, 2026

Am J Physiol Cell Physiol

Abstract Endotrophin, a biologically active fragment derived from the α3 chain of collagen type VI, has emerged as both a risk biomarker and a potential pathogenic factor in cardiovascular-kidney-metabolic (CKM) syndrome. Over the past decade, research has shed light on its role in various noncommunicable diseases, emphasizing its signaling properties and diagnostic potential. Despite these […]

Read publication